- Home
- PRQR vs SOR Comparison
PRQR vs SOR Comparison
Compare PRQR & SOR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PRQR
- SOR
- Stock Information
- Founded
- PRQR 2012
- SOR 1968
- Country
- PRQR Netherlands
- SOR United States
- Employees
- PRQR N/A
- SOR N/A
- Industry
- PRQR Biotechnology: Pharmaceutical Preparations
- SOR Investment Managers
- Sector
- PRQR Health Care
- SOR Finance
- Exchange
- PRQR Nasdaq
- SOR Nasdaq
- Market Cap
- PRQR 232.8M
- SOR 368.8M
- IPO Year
- PRQR 2014
- SOR N/A
- Fundamental
- Price
- PRQR $2.06
- SOR $45.01
- Analyst Decision
- PRQR Strong Buy
- SOR
- Analyst Count
- PRQR 8
- SOR 0
- Target Price
- PRQR $8.88
- SOR N/A
- AVG Volume (30 Days)
- PRQR 368.1K
- SOR 16.2K
- Earning Date
- PRQR 11-06-2025
- SOR 01-01-0001
- Dividend Yield
- PRQR N/A
- SOR 7.24%
- EPS Growth
- PRQR N/A
- SOR N/A
- EPS
- PRQR N/A
- SOR 6.50
- Revenue
- PRQR $20,129,184.00
- SOR N/A
- Revenue This Year
- PRQR N/A
- SOR N/A
- Revenue Next Year
- PRQR N/A
- SOR N/A
- P/E Ratio
- PRQR N/A
- SOR $6.41
- Revenue Growth
- PRQR 8.65
- SOR N/A
- 52 Week Low
- PRQR $1.07
- SOR $36.41
- 52 Week High
- PRQR $4.62
- SOR $42.75
- Technical
- Relative Strength Index (RSI)
- PRQR 42.63
- SOR 62.24
- Support Level
- PRQR $1.91
- SOR $44.69
- Resistance Level
- PRQR $2.50
- SOR $45.74
- Average True Range (ATR)
- PRQR 0.16
- SOR 0.58
- MACD
- PRQR -0.04
- SOR 0.02
- Stochastic Oscillator
- PRQR 25.42
- SOR 52.63
About PRQR ProQR Therapeutics N.V.
ProQR Therapeutics NV is a biopharmaceutical company. It discovers and develops RNA therapeutics for patients with severe genetic rare diseases such as cystic fibrosis, Leber congenital amaurosis type 10, and dystrophic epidermolysis bullosa. The only reportable segment of the company is the discovery and development of different, RNA-based therapeutics.
About SOR Source Capital Inc.
Source Capital Inc is a diversified, closed-end management investment company. The investment objective of the company is to seek maximum total return for Common shareholders from both capital appreciation and investment income to the extent consistent with the protection of invested capital.